Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
over-the-counter (OTC) branded and generic<br />
loratadine (Claritin) allergy products since Claritin<br />
became an OTC product in November 2002, and a<br />
weak spring allergy season. Allegra / Telfast sales in<br />
Japan were driven by growth in allergic rhinitis and<br />
skin disease, resulting from focused sales force and<br />
professional education efforts aimed at enhancing<br />
brand credibility with physicians.<br />
Global sales of Lovenox / Clexane grew 21.3 % on<br />
an activity basis due to strong sales performance in<br />
the U.S. and Europe. Lovenox / Clexane remains the<br />
market leader in terms of sales value in each of the<br />
major European markets, achieving double-digit<br />
growth in <strong>2003</strong> and continuing to expand sales in<br />
the open care segment.<br />
Taxotere sales grew 22.5 % on an activity basis.<br />
This was due to strong performance in all markets,<br />
spearheaded by the U.S., where sales benefi ted from<br />
increased usage in metastatic breast cancer and fi rstline<br />
non-small-cell lung cancer (NSCLC). Taxotere<br />
sales in Germany were supported by the launch in<br />
fi rst-line NSCLC and by increased sales force focus<br />
through our establishment of separate oncology<br />
sales lines and optimized customer targeting and<br />
segmentation. More than 250 abstracts on Taxotere<br />
presented at the 39th American Society of Clinical<br />
Oncology (ASCO) in June <strong>2003</strong> increased awareness<br />
of Taxotere within the medical community.<br />
Delix / Tritace sales grew 20.6% on an activity basis<br />
to e 1 066 million, achieving blockbuster status<br />
for the fi rst time. Delix / Tritace outperformed all<br />
competing ACE inhibitors in terms of sales volume,<br />
growing by 24 % in total prescriptions worldwide (excluding<br />
the U.S. and Japan) during the 12 month<br />
period from Q4 2002 through Q3 <strong>2003</strong>. Market share<br />
for Delix / Tritace increased in all key segments with<br />
particularly strong growth in diabetes and cardiovascular<br />
risk. Sales growth was primarily driven by<br />
strong performance in the UK, Canada and France.<br />
A key factor in the global sales growth of Delix /<br />
Tritace in <strong>2003</strong> was increased use of Delix / Tritace<br />
10 mg, based on the clinical fi ndings of the MITRA<br />
PLUS and HOPE studies that demonstrated its<br />
superiority over other ACE inhibitors.<br />
>> 50